Search results for "DMI"

showing 10 items of 7539 documents

Effects of cigarette smoking or ingestion of nicotine on platelet 5-hydroxytryptamine (5-HT) levels in smokers and non-smokers.

1992

Platelets of healthy smokers and non-smokers were prepared and their content of 5-hydroxytryptamine was determined by HPLC with electrochemical detection. Platelet 5-HT levels in smokers (728 +/- 156 pmol per 10(8) platelets, mean +/- SEM, n = 9) were significantly higher than those in non-smokers (353 +/- 156 pmol per 10(8) platelets, n = 11). Smoking of a single cigarette caused a transient increase in platelet 5-HT levels by about 350% in non-smokers, but had no additional effect in smokers. Similarly, chewing of nicotine gum (4-8 mg nicotine) resulted in a transient increase in platelet 5-HT by about 100% in non-smokers, but not in smokers. In conclusion, smoking of cigarettes can cause…

AdultBlood Plateletsmedicine.medical_specialtyNicotineSerotoninAdministration OralReceptors NicotinicNicotine03 medical and health sciences0302 clinical medicineCigarette smokingInternal medicineDrug DiscoverymedicineEnterochromaffin CellsIngestionHumansPlateletReceptorGenetics (clinical)5-HT receptorbusiness.industrySmokingGeneral Medicinerespiratory tract diseases3. Good healthEndocrinologyNicotine gum030220 oncology & carcinogenesisReceptors Serotoninbehavior and behavior mechanismsMolecular MedicineSerotoninbusiness030217 neurology & neurosurgerymedicine.drugThe Clinical investigator
researchProduct

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with plati…

2004

OBJECTIVES: There is an urgent need for new agents with activity in platinum- and taxane-resistant epithelial ovarian cancer. Exatecan mesylate is a novel topoisomerase I inhibitor with potent activity against ovarian cancer in vitro. A multicentre phase IIA study was conducted in patients with platinum- and taxane-resistant epithelial ovarian cancer. PATIENTS AND METHODS: Fifty-seven patients with bidimensionally measurable ovarian cancer, previously exposed to platinum and taxanes, whose disease had relapsed within 6 months of platinum-containing chemotherapy were randomised to one of two intravenous schedules of exatecan mesylate; 0.3 mg/m(2) daily for 5 days every 3 weeks (Arm A) or 2.1…

AdultBridged-Ring Compoundsmedicine.medical_specialtyOrganoplatinum Compoundsmedicine.medical_treatmentPharmacologyNeutropeniaGastroenterologyDrug Administration Schedulechemistry.chemical_compoundRefractoryInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansExatecanEnzyme InhibitorsAgedOvarian NeoplasmsChemotherapyTaxanebusiness.industryObstetrics and GynecologyExatecan mesylateMiddle Agedmedicine.diseaseAntineoplastic Agents PhytogenicDrug Resistance MultipleRegimenOncologychemistryDrug Resistance NeoplasmCamptothecinFemaleTaxoidsTopoisomerase I InhibitorsbusinessOvarian cancer
researchProduct

The A allele of cluster of differentiation 36 (CD36) SNP 1761667 associates with decreased lipid taste perception in obese Tunisian women.

2015

Recent studies have suggested that excessive intake of dietary fat is associated with obesity. Some obese subjects have been reported to exhibit high thresholds for the gustatory detection of lipids via lipid receptors, such as cluster of differentiation 36 (CD36). We studied lingual detection thresholds for emulsions containing oleic acid in obese Tunisian women (n203) using a three-alternative forced choice (3-AFC) method. Genotyping of theTNF-α(rs1800629),IL-6(rs1800795) andCD36(rs1761667) genes was performed to associate with lipid taste perception thresholds. TheCD36genotype distribution was as follows: GG (n42), AG (n102) and AA (n59). Women with theCD36GG genotype exhibited oral dete…

AdultCD36 AntigensTastemedicine.medical_specialtyTunisiaGenotypeCD36Medicine (miscellaneous)Administration OralBiologyPolymorphism Single Nucleotidechemistry.chemical_compoundFood PreferencesInternal medicineGenotypemedicineSNPCluster AnalysisHumansObesityAllele10. No inequalityGenotypingAllelesGeneticsNutrition and DieteticsInterleukin-6Tumor Necrosis Factor-alphaTaste PerceptionMiddle Agedmedicine.diseaseTaste BudsObesityDietary FatsOleic acidEndocrinologychemistryTastebiology.proteinFemaleOleic AcidThe British journal of nutrition
researchProduct

Inhibition of dextromethorphan metabolism by moclobemide.

1998

This pilot study was conducted to evaluate the potential of the new antidepressant moclobemide to inhibit the cytochrome enzyme P4502D6 (CYP2D6) using the cough suppressant dextromethorphan as a substrate in four extensive metabolizers (EM) of debrisoquine. The subjects received seven oral doses of 20 mg dextromethorphan at 4-h intervals over 2 days (1 and 2) and subsequently moclobemide (300 mg b.i.d.) for 9 days. On days 10 and 11, they received seven doses of 20 mg dextromethorphan in addition to moclobemide. During monotreatment and combined treatment, blood was collected on days 2 and 11, respectively, for determination of dextromethorphan and its demethylated metabolites using automat…

AdultCYP2D6animal structuresMonoamine Oxidase InhibitorsAdolescentMoclobemidePharmacologyDextromethorphanchemistry.chemical_compoundPharmacokineticsOral administrationDextrorphanMoclobemideMedicineHumansDrug InteractionsBiotransformationPharmacologybusiness.industryDextromethorphanDrug interactionAntidepressive AgentsDebrisoquinechemistryArea Under CurveBenzamidesbusinessmedicine.drugPsychopharmacology
researchProduct

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematolog…

2006

Abstract Purpose: LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle. Experimental Design: Fifteen patients (median age, 63 years; range, 42-87 years) with acute myeloid leukemia (13 patients), acute lymphocytic leukemia (1 patient), or myelodysplastic syndrome (1 patient) were treated with LBH589 at the following dose levels (mg/m2): 4.8 (3 patients), 7.2 (3 patients), 9.0 (1 patient), 11.5 (3 patient), and 14.0 (5 patients). The levels of histone acetylation were measured using quantitative flow cytometry and plasm…

AdultCancer ResearchIndolesMaximum Tolerated Dosemedicine.drug_classApoptosisPharmacologyHydroxamic AcidsDrug Administration ScheduleHistonesStructure-Activity Relationshipchemistry.chemical_compoundPredictive Value of TestsPanobinostatAcute lymphocytic leukemiaPanobinostatBiomarkers TumormedicineHumansEnzyme InhibitorsAgedCell ProliferationAged 80 and overDose-Response Relationship Drugbusiness.industryHistone deacetylase inhibitorArea under the curveQTcF ProlongationMyeloid leukemiaMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHypokalemiaHistone Deacetylase InhibitorsLeukemiaTreatment OutcomeOncologychemistryCinnamatesLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseInjections IntravenousImmunologymedicine.symptombusinessFollow-Up StudiesClinical Cancer Research
researchProduct

Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.

2002

PURPOSE: To study safety, feasibility, and biologic activity of adenovirus-mediated p53 gene transfer in patients with bladder cancer. PATIENTS AND METHODS: Twelve patients with histologically confirmed bladder cancer scheduled for cystectomy were treated on day 1 with a single intratumoral injection of SCH 58500 (rAd/p53) at cystoscopy at one dose level (7.5 × 1011 particles) or a single intravesical instillation of SCH 58500 with a transduction-enhancing agent (Big CHAP) at three dose levels (7.5 × 1011 to 7.5 × 1013 particles). Cystectomies were performed in 11 patients on day 3, and transgene expression, vector distribution, and biologic markers of transgene activity were assessed by m…

AdultCancer ResearchPathologymedicine.medical_specialtymedicine.medical_treatmentGenetic enhancementGenetic VectorsUrologyCystectomyAdenoviridaeCystectomymedicineHumansNeoplasm InvasivenessAgedDNA PrimersBiologic markerAged 80 and overUrinary bladderBladder cancermedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryReverse Transcriptase Polymerase Chain ReactionGenetic transferGene Transfer TechniquesCystoscopyGenetic TherapyMiddle Agedmedicine.diseaseGenes p53medicine.anatomical_structureAdministration IntravesicalOncologyUrinary Bladder NeoplasmsImmunohistochemistrybusinessJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).

2007

Persistent infection with human papillomaviruses (HPV) is a prerequisite for the development of cervical cancer. Vaccination with virus-like particles (VLP) has demonstrated efficacy in prophylaxis but lacks therapeutic potential. HPV16 L1E7 chimeric virus-like particles (CVLP) consist of a carboxy-terminally truncated HPV16L1 protein fused to the amino-terminal part of the HPV16 E7 protein and self-assemble by recombinant expression of the fusion protein. The CVLP are able to induce L1- and E7-specific cytotoxic T lymphocytes. We have performed a first clinical trial to gain information about the safety and to generate preliminary data on the therapeutic potential of the CVLP in humans. A …

AdultCancer ResearchTime FactorsOncogene Proteins FusionvirusesUterine Cervical NeoplasmsCervical intraepithelial neoplasiaCancer VaccinesDrug Administration ScheduleDouble-Blind MethodMedicineHumansPapillomavirus VaccinesAdverse effectAgedCervical cancerHuman papillomavirus 16biologybusiness.industryPapillomavirus Infectionsvirus diseasesOncogene Proteins ViralMiddle Agedmedicine.diseaseUterine Cervical Dysplasiafemale genital diseases and pregnancy complicationsVaccinationClinical trialTumor Virus InfectionsTreatment OutcomeOncologyImmunizationHigh Grade Cervical Intraepithelial NeoplasiaImmunologyDNA Viralbiology.proteinFemaleAntibodybusinessInternational journal of cancer
researchProduct

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as …

2005

The sequential doxorubicin → CMF (CMF = cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF × 6 cycles (A → CMF); (c) CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (CMF → GT); and (d) doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (A → CMF → GT). The study used a 2 × 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A …

AdultCancer Researchmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentUrologyBreast NeoplasmsDisease-Free SurvivalDrug Administration Schedulebreast cancerchemoendocrine treatmentAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineAdjuvant therapyHumansDoxorubicinCyclophosphamideanthracyclinesGynecologyChemotherapypremenopausalbusiness.industryGoserelinadjuvant therapyMiddle AgedCombined Modality TherapyTamoxifenRegimenMethotrexateOncologyChemotherapy AdjuvantDoxorubicinFluorouracilLymphatic MetastasisGoserelinFemaleFluorouracilbusinessTamoxifenFollow-Up Studiesmedicine.drugBritish Journal of Cancer
researchProduct

Skin-PAMPA: a new method for fast prediction of skin penetration.

2011

The goal of this study was to develop a quick, reliable, and cost-effective permeability model for predicting transdermal penetration of compounds. The Parallel Artificial Membrane Permeability Assay (PAMPA) was chosen for this purpose, as it already has been successfully used for estimating passive gastrointestinal absorption and blood-brain barrier permeability. To match the permeability of the rate-limiting barrier in human skin, synthetic certramides, which are analogs of the ceramides present in the stratum corneum, were selected for the skin-PAMPA model. The final skin-PAMPA membrane lipid mixture (certramide, free fatty acid, and cholesterol) was selected and optimized based on data …

AdultCell Membrane PermeabilityDatabases FactualTransdermal penetrationSkin AbsorptionSynthetic membranePharmaceutical ScienceHuman skinAdministration CutaneousCeramidesModels BiologicalMembrane LipidsDrug DiscoveryStratum corneummedicineHumansSkinChromatographyintegumentary systemChemistryReproducibility of ResultsMembranes ArtificialMiddle AgedLipid MetabolismPermeability (earth sciences)medicine.anatomical_structureMembraneSkin penetrationBarrier permeabilityEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Inhibition of skin inflammation by baicalin ultradeformable vesicles.

2016

The topical efficacy of baicalin, a natural flavonoid isolated from Scutellaria baicalensis Georgi, which has several beneficial properties, such as antioxidative, antiviral, anti-inflammatory and antiproliferative, is hindered by its poor aqueous solubility and low skin permeability. Therefore, its incorporation into appropriate phospholipid vesicles could be a useful tool to improve its local activity. To this purpose, baicalin at increasing concentrations up to saturation, was incorporated in ultradeformable vesicles, which were small in size (∼67nm), monodispersed (PI<0.19) and biocompatible, regardless of the concentration of baicalin, as confirmed by in vitro studies using fibroblasts…

AdultCell SurvivalSkin AbsorptionPharmaceutical ScienceDermatitis02 engineering and technologyPharmacologyAdministration Cutaneous03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineIn vivomedicineAnimalsHumansDexamethasoneTransdermalFlavonoidsDrug CarriersbiologyEpidermis (botany)Vesicle3T3 CellsMiddle Aged021001 nanoscience & nanotechnologybiology.organism_classificationIn vitrochemistry030220 oncology & carcinogenesisScutellaria baicalensisFemale0210 nano-technologyBaicalinmedicine.drugInternational journal of pharmaceutics
researchProduct